Effect of Cimetidine on Survival after gastric cancer

Research output: Contribution to journalArticle

Abstract

The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

Details

Authors
  • Hanne Tonnesen
  • Steffen Bülow
  • Kaj Fischerman
  • Allan Hjortrup
  • Vilhelm Møller Pedersen
  • Lars Bo Svendsen
  • Ulrich Knigge
  • Peter Damm
  • Peter Hesselfeldt
  • Ib Krogh Pedersen
  • Ole Julius Siemssen
  • Poul Martin Christiansen
External organisations
  • Hvidovre Hospital
  • Copenhagen University Hospital
  • University Hospital Amager
  • Gentofte Hospital
  • Bispebjerg Hospital
  • Kommunehospitalet
  • Frederiksberg Hospital
  • Glostrup Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)990-992
Number of pages3
JournalThe Lancet
Volume332
Issue number8618
Publication statusPublished - 1988 Oct 29
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes